Search

Your search keyword '"Fine, Bernard M."' showing total 49 results
Start Over Author "Fine, Bernard M."
49 results on '"Fine, Bernard M."'

1. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Author

Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S. N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J. A., and de Vries, Elisabeth G. E.

Published
2022
Full Text
View/download PDF

2. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Author

Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., Oosting, Sjoukje F., Schröder, Carolina P., Hiltermann, T. Jeroen N., van der Wekken, Anthonie J., Groen, Harry J. M., Kwee, Thomas C., Elias, Sjoerd G., Gietema, Jourik A., Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon-Peter, Mancao, Christoph, Brouwers, Adrienne H., Fine, Bernard M., and de Vries, Elisabeth G. E.

Published
2018
Full Text
View/download PDF

4. Supplementary Table 2 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Author

Punnoose, Elizabeth A., primary, Atwal, Siminder, primary, Liu, Weiqun, primary, Raja, Rajiv, primary, Fine, Bernard M., primary, Hughes, Brett G.M., primary, Hicks, Rodney J., primary, Hampton, Garret M., primary, Amler, Lukas C., primary, Pirzkall, Andrea, primary, and Lackner, Mark R., primary

Published
2023
Full Text
View/download PDF

5. Supplementary figure legend from ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Author

Lamberts, Laetitia E., primary, Menke-van der Houven van Oordt, Catharina W., primary, ter Weele, Eva J., primary, Bensch, Frederike, primary, Smeenk, Michiel M., primary, Voortman, Johannes, primary, Hoekstra, Otto S., primary, Williams, Simon P., primary, Fine, Bernard M., primary, Maslyar, Daniel, primary, de Jong, Johan R., primary, Gietema, Jourik A., primary, Schröder, Carolien P., primary, Bongaerts, Alphons H.H., primary, Lub-de Hooge, Marjolijn N., primary, Verheul, Henk M.W., primary, Sanabria Bohorquez, Sandra M., primary, Glaudemans, Andor W.J.M., primary, and de Vries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

6. Supplementary figure 1A from ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Author

Lamberts, Laetitia E., primary, Menke-van der Houven van Oordt, Catharina W., primary, ter Weele, Eva J., primary, Bensch, Frederike, primary, Smeenk, Michiel M., primary, Voortman, Johannes, primary, Hoekstra, Otto S., primary, Williams, Simon P., primary, Fine, Bernard M., primary, Maslyar, Daniel, primary, de Jong, Johan R., primary, Gietema, Jourik A., primary, Schröder, Carolien P., primary, Bongaerts, Alphons H.H., primary, Lub-de Hooge, Marjolijn N., primary, Verheul, Henk M.W., primary, Sanabria Bohorquez, Sandra M., primary, Glaudemans, Andor W.J.M., primary, and de Vries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Table 1 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Author

Punnoose, Elizabeth A., primary, Atwal, Siminder, primary, Liu, Weiqun, primary, Raja, Rajiv, primary, Fine, Bernard M., primary, Hughes, Brett G.M., primary, Hicks, Rodney J., primary, Hampton, Garret M., primary, Amler, Lukas C., primary, Pirzkall, Andrea, primary, and Lackner, Mark R., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figures 1-2 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Author

Punnoose, Elizabeth A., primary, Atwal, Siminder, primary, Liu, Weiqun, primary, Raja, Rajiv, primary, Fine, Bernard M., primary, Hughes, Brett G.M., primary, Hicks, Rodney J., primary, Hampton, Garret M., primary, Amler, Lukas C., primary, Pirzkall, Andrea, primary, and Lackner, Mark R., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 3 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Author

Punnoose, Elizabeth A., primary, Atwal, Siminder, primary, Liu, Weiqun, primary, Raja, Rajiv, primary, Fine, Bernard M., primary, Hughes, Brett G.M., primary, Hicks, Rodney J., primary, Hampton, Garret M., primary, Amler, Lukas C., primary, Pirzkall, Andrea, primary, and Lackner, Mark R., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data from Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

Author

Mileshkin, Linda, primary, Hicks, Rodney J., primary, Hughes, Brett G.M., primary, Mitchell, Paul L.R., primary, Charu, Veena, primary, Gitlitz, Barbara J., primary, Macfarlane, David, primary, Solomon, Benjamin, primary, Amler, Lukas C., primary, Yu, Wei, primary, Pirzkall, Andrea, primary, and Fine, Bernard M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Tables S1-S4 from A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients

Author

Dai, Hongyue, primary, van't Veer, Laura, primary, Lamb, John, primary, He, Yudong D., primary, Mao, Mao, primary, Fine, Bernard M., primary, Bernards, Rene, primary, van de Vijver, Marc, primary, Deutsch, Paul, primary, Sachs, Alan, primary, Stoughton, Roland, primary, and Friend, Stephen, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figures S1-S10 from A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients

Author

Dai, Hongyue, primary, van't Veer, Laura, primary, Lamb, John, primary, He, Yudong D., primary, Mao, Mao, primary, Fine, Bernard M., primary, Bernards, Rene, primary, van de Vijver, Marc, primary, Deutsch, Paul, primary, Sachs, Alan, primary, Stoughton, Roland, primary, and Friend, Stephen, primary

Published
2023
Full Text
View/download PDF

15. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Author

Hart- en Vaatziekten Team A, Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S.N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J.A., de Vries, Elisabeth G.E., Hart- en Vaatziekten Team A, Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S.N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J.A., and de Vries, Elisabeth G.E.

Published
2022

18. Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor

Author

de Ruijter, Laura Kist, primary, van de Donk, Pim P., additional, Hooiveld-Noeken, Jahlisa S., additional, Giesen, Danique, additional, Ungewickell, Alexander, additional, Fine, Bernard M., additional, Williams, Simon P., additional, Bohorquez, Sandra M. Sanabria, additional, Yadav, Mahesh, additional, Koeppen, Hartmut, additional, Jing, Jing, additional, Guelman, Sebastian, additional, Lin, Mark T., additional, Mamounas, Michael J., additional, Eastham, Jeffrey, additional, Kimes, Patrick K., additional, Glaudemans, Andor W., additional, Brouwers, Adrienne H., additional, Lub-de Hooge, Marjolijn N., additional, Gietema, Jourik A., additional, Schröder, Carolina P., additional, Timens, Wim, additional, Jalving, Mathilde, additional, Elias, Sjoerd, additional, Oosting, Sjoukje F., additional, de Groot, Derk J., additional, and de Vries, Elisabeth G., additional

Published
2021
Full Text
View/download PDF

19. Whole-body CD8+T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Author

Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S. N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J. A., and de Vries, Elisabeth G. E.

Abstract

Immune checkpoint inhibitors (ICIs), by reinvigorating CD8+T cell mediated immunity, have revolutionized cancer therapy. Yet, the systemic CD8+T cell distribution, a potential biomarker of ICI response, remains poorly characterized. We assessed safety, imaging dose and timing, pharmacokinetics and immunogenicity of zirconium-89-labeled, CD8-specific, one-armed antibody positron emission tomography tracer 89ZED88082A in patients with solid tumors before and ~30 days after starting ICI therapy (NCT04029181). No tracer-related side effects occurred. Positron emission tomography imaging with 10 mg antibody revealed 89ZED88082A uptake in normal lymphoid tissues, and tumor lesions across the body varying within and between patients two days after tracer injection (n= 38, median patient maximum standard uptake value (SUVmax) 5.2, IQI 4.0–7.4). Higher SUVmaxwas associated with mismatch repair deficiency and longer overall survival. Uptake was higher in lesions with stromal/inflamed than desert immunophenotype. Tissue radioactivity was localized to areas with immunohistochemically confirmed CD8 expression. Re-imaging patients on treatment showed no change in average (geometric mean) tumor tracer uptake compared to baseline, but individual lesions showed diverse changes independent of tumor response. The imaging data suggest enormous heterogeneity in CD8+T cell distribution and pharmacodynamics within and between patients. In conclusion, 89ZED88082A can characterize the complex dynamics of CD8+T cells in the context of ICIs, and may inform immunotherapeutic treatments.

Published
2022
Full Text
View/download PDF

20. Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Author

Cohen, Adam D., primary, Harrison, Simon J, additional, Krishnan, Amrita, additional, Fonseca, Rafael, additional, Forsberg, Peter A, additional, Spencer, Andrew, additional, Berdeja, Jesus G., additional, Laubach, Jacob P., additional, Li, Mengsong, additional, Choeurng, Voleak, additional, Vaze, Anjali, additional, Samineni, Divya, additional, Sumiyoshi, Teiko, additional, Cooper, James, additional, Fine, Bernard M, additional, and Trudel, Suzanne, additional

Published
2020
Full Text
View/download PDF

21. Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Author

Nakamura, Rin, primary, Lear, Sean, additional, Wilson, Deanna, additional, Koeppen, Hartmut, additional, Vaze, Anjali, additional, Trudel, Suzanne, additional, Spencer, Andrew, additional, Harrison, Simon J, additional, Cohen, Adam D., additional, Fine, Bernard M, additional, Li, Mengsong, additional, Cooper, James, additional, and Sumiyoshi, Teiko, additional

Published
2020
Full Text
View/download PDF

24. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer

Author

Danila, Daniel C., primary, Szmulewitz, Russell Z., additional, Vaishampayan, Ulka, additional, Higano, Celestia S., additional, Baron, Ari D., additional, Gilbert, Houston N., additional, Brunstein, Flavia, additional, Milojic-Blair, Marija, additional, Wang, Bei, additional, Kabbarah, Omar, additional, Mamounas, Michael, additional, Fine, Bernard M., additional, Maslyar, Daniel J., additional, Ungewickell, Alexander, additional, and Scher, Howard I., additional

Published
2019
Full Text
View/download PDF

27. Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients

Author

O’Donoghue, Joseph A., primary, Danila, Daniel C., additional, Pandit-Taskar, Neeta, additional, Beylergil, Volkan, additional, Cheal, Sarah M., additional, Fleming, Stephen E., additional, Fox, Josef J., additional, Ruan, Shutian, additional, Zanzonico, Pat B., additional, Ragupathi, Govind, additional, Lyashchenko, Serge K., additional, Williams, Simon P., additional, Scher, Howard I., additional, Fine, Bernard M., additional, Humm, John L., additional, Larson, Steven M., additional, Morris, Michael J., additional, and Carrasquillo, Jorge A., additional

Published
2019
Full Text
View/download PDF

28. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody

Author

Carrasquillo, Jorge A., primary, Fine, Bernard M., additional, Pandit-Taskar, Neeta, additional, Larson, Steven M., additional, Fleming, Stephen E., additional, Fox, Josef J., additional, Cheal, Sarah M., additional, O’Donoghue, Joseph A., additional, Ruan, Shutian, additional, Ragupathi, Govind, additional, Lyashchenko, Serge K., additional, Humm, John L., additional, Scher, Howard I., additional, Gönen, Mithat, additional, Williams, Simon P., additional, Danila, Daniel C., additional, and Morris, Michael J., additional

Published
2019
Full Text
View/download PDF

29. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Author

MS Hematologie, RF&S Team 1 Medisch, Brain, Epi Kanker, UMC Utrecht, Cancer, JC onderzoeksprogramma Kanker, Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., Oosting, Sjoukje F., Schröder, Carolina P., Hiltermann, T. Jeroen N., van der Wekken, Anthonie J., Groen, Harry J.M., Kwee, Thomas C., Elias, Sjoerd G., Gietema, Jourik A., Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon Peter, Mancao, Christoph, Brouwers, Adrienne H., Fine, Bernard M., de Vries, Elisabeth G.E., MS Hematologie, RF&S Team 1 Medisch, Brain, Epi Kanker, UMC Utrecht, Cancer, JC onderzoeksprogramma Kanker, Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., Oosting, Sjoukje F., Schröder, Carolina P., Hiltermann, T. Jeroen N., van der Wekken, Anthonie J., Groen, Harry J.M., Kwee, Thomas C., Elias, Sjoerd G., Gietema, Jourik A., Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon Peter, Mancao, Christoph, Brouwers, Adrienne H., Fine, Bernard M., and de Vries, Elisabeth G.E.

Published
2018

32. Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

Author

O'Donoghue, Joseph A., Danila, Daniel C., Pandit-Taskar, Neeta, Beylergil, Volkan, Cheal, Sarah M., Fleming, Stephen E., Fox, Josef J., Ruan, Shutian, Zanzonico, Pat B., Ragupathi, Govind, Lyashchenko, Serge K., Williams, Simon P., Scher, Howard I., Fine, Bernard M., Humm, John L., Larson, Steven M., Morris, Michael J., and Carrasquillo, Jorge A.

Published
2019
Full Text
View/download PDF

33. Static structure factor and collective diffusion of globular proteins in concentrated aqueous solution.

Author

Fine, Bernard M., Lomakin, Aleksey, Ogun, Olutayo O., and Benedek, George B.

Subjects
*GLOBULAR proteins, *MOLECULAR structure, *HYDRODYNAMICS
Abstract

We report our measurement of the time average and the temporal autocorrelation function of the intensity of light scattered by the highly monomeric globular protein, bovine γII-crystallin, in aqueous solution as a function of wave number q, protein volume fraction [lowercase_phi_synonym], and temperature T. The time average intensity data is used to obtain the q→0 limit of the static structure factor S([lowercase_phi_synonym],T), as a function of [lowercase_phi_synonym] and T. We show that S([lowercase_phi_synonym],T) may be well characterized by modeling the proteins as interacting through the Baxter adhesive hard sphere pair interaction potential. The temporal autocorrelation function data is used to determine the collective diffusion coefficient D([lowercase_phi_synonym],T) of the proteins as a function of [lowercase_phi_synonym] and T. We then obtain the experimental hydrodynamic factor H([lowercase_phi_synonym],T)≡S([lowercase_phi_synonym],T)[D([lowercase_phi_synonym],T)/D0(T)], where D0(T) is the diffusion coefficient of the individual proteins in the [lowercase_phi_synonym]→0 limit. We find that H exhibits a different [lowercase_phi_synonym]-dependence at low ([lowercase_phi_synonym]≤0.016) and high ([lowercase_phi_synonym]>=0.02) protein volume fractions. In the low [lowercase_phi_synonym] domain our data for H are consistent with the theoretical result for the collective diffusion in the q→0, t→0 limit. However, for [lowercase_phi_synonym]>=0.02 we find a deviation from single exponential decay in the autocorrelation functions, and an unexpected, large change in the slope of the H vs [lowercase_phi_synonym] relation. This crossover at such low [lowercase_phi_synonym] suggests the existence of a heretofore unappreciated length scale in the dynamics of colloid solutions.... [ABSTRACT FROM AUTHOR]

Published
1996
Full Text
View/download PDF

34. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Author

Lamberts, Laetitia E., primary, Menke-van der Houven van Oordt, Catharina W., additional, ter Weele, Eva J., additional, Bensch, Frederike, additional, Smeenk, Michiel M., additional, Voortman, Johannes, additional, Hoekstra, Otto S., additional, Williams, Simon P., additional, Fine, Bernard M., additional, Maslyar, Daniel, additional, de Jong, Johan R., additional, Gietema, Jourik A., additional, Schröder, Carolien P., additional, Bongaerts, Alphons H.H., additional, Lub-de Hooge, Marjolijn N., additional, Verheul, Henk M.W., additional, Sanabria Bohorquez, Sandra M., additional, Glaudemans, Andor W.J.M., additional, and de Vries, Elisabeth G.E., additional

Published
2016
Full Text
View/download PDF

35. STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC).

Author

Danila, Daniel Costin, primary, Fleisher, Martin, additional, Carrasquillo, Jorge A., additional, Gilbert, Houston, additional, Morris, Michael J., additional, Bellomo, Lawrence P, additional, Hendrikx, Petrus J, additional, Szafer-Glusman, Edith, additional, Herkal, Amrita, additional, Patel, Chintan, additional, Schreiber, Nicole A., additional, Curtis, Kristen Rebecca, additional, Maslyar, Daniel J., additional, Lemahieu, Vanessa, additional, Fine, Bernard M., additional, Mamounas, Michael J., additional, Ungewickell, Alexander Joachim, additional, Lackner, Mark R., additional, Scher, Howard I., additional, and Kabbarah, Omar, additional

Published
2015
Full Text
View/download PDF

36. Abstract 2069: Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients

Author

Carrasquillo, Jorge A., primary, Danila, Daniel C., additional, Beylergil, Volkan, additional, O'Donoghue, Joseph A., additional, Cheal, Sarah M., additional, Ruan, Shutian, additional, Pandit-Taskar, Neeta, additional, Fox, Josef J., additional, Fleming, Stephen E., additional, Zanzonico, Pat B., additional, Ragupathi, Govind, additional, Lyashchenko, Serge K., additional, William, Simon P., additional, Larson, Steven M., additional, Scher, Howard I., additional, Fine, Bernard M., additional, and Morris, Michael J., additional

Published
2014
Full Text
View/download PDF

37. A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Author

Danila, Daniel Costin, primary, Szmulewitz, Russell Zelig, additional, Baron, Ari David, additional, Higano, Celestia S., additional, Scher, Howard I., additional, Morris, Michael J., additional, Gilbert, Houston, additional, Brunstein, Flavia, additional, Lemahieu, Vanessa, additional, Kabbarah, Omar, additional, Fine, Bernard M., additional, Maslyar, Daniel J., additional, and Vaishampayan, Ulka N., additional

Published
2014
Full Text
View/download PDF

38. Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging

Author

Hughes, Brett, primary, Mileshkin, Linda, additional, Townley, Peter, additional, Gitlitz, Barbara, additional, Eaton, Keith, additional, Mitchell, Paul, additional, Hicks, Rodney, additional, Wood, Katie, additional, Amler, Lucas, additional, Fine, Bernard M., additional, Loecke, David, additional, and Pirzkall, Andrea, additional

Published
2014
Full Text
View/download PDF

39. A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Author

Danila, Daniel Costin, primary, Szmulewitz, Russell Zelig, additional, Higano, Celestia S., additional, Gilbert, Houston, additional, Kahn, Robert S., additional, Wood, Katie, additional, Agarwal, Priya, additional, Lin, Kedan, additional, Kabbarah, Omar, additional, Fine, Bernard M., additional, Maslyar, Daniel J., additional, and Vaishampayan, Ulka N., additional

Published
2013
Full Text
View/download PDF

40. Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Author

Punnoose, Elizabeth A., primary, Atwal, Siminder, additional, Liu, Weiqun, additional, Raja, Rajiv, additional, Fine, Bernard M., additional, Hughes, Brett G.M., additional, Hicks, Rodney J., additional, Hampton, Garret M., additional, Amler, Lukas C., additional, Pirzkall, Andrea, additional, and Lackner, Mark R., additional

Published
2012
Full Text
View/download PDF

41. Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

Author

Mileshkin, Linda, primary, Hicks, Rodney J., additional, Hughes, Brett G.M., additional, Mitchell, Paul L.R., additional, Charu, Veena, additional, Gitlitz, Barbara J., additional, Macfarlane, David, additional, Solomon, Benjamin, additional, Amler, Lukas C., additional, Yu, Wei, additional, Pirzkall, Andrea, additional, and Fine, Bernard M., additional

Published
2011
Full Text
View/download PDF

42. Molecular Biomarker Analyses Using Circulating Tumor Cells

Author

Punnoose, Elizabeth A., primary, Atwal, Siminder K., additional, Spoerke, Jill M., additional, Savage, Heidi, additional, Pandita, Ajay, additional, Yeh, Ru-Fang, additional, Pirzkall, Andrea, additional, Fine, Bernard M., additional, Amler, Lukas C., additional, Chen, Daniel S., additional, and Lackner, Mark R., additional

Published
2010
Full Text
View/download PDF

43. A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients

Author

Dai, Hongyue, primary, van't Veer, Laura, additional, Lamb, John, additional, He, Yudong D., additional, Mao, Mao, additional, Fine, Bernard M., additional, Bernards, Rene, additional, van de Vijver, Marc, additional, Deutsch, Paul, additional, Sachs, Alan, additional, Stoughton, Roland, additional, and Friend, Stephen, additional

Published
2005
Full Text
View/download PDF

46. Discussion: “Organizing for Industrial Preparedness” (Miller, Spencer, 1916, Trans. ASME, 38, pp. 47–54)

Author

Baker, Charles Whiting, Gilbreth, Frank B., Peabody, Ernest H., Smith, Oberlin, Barr, John H., Campbell, James A., Hoagland, F. O., Haight, H. V., Wells, Fhank O., Smart, Charles E., Younger, John, Fine, Bernard M., Dennis, Alfred L. P., McKee, Arthur G., Harris, Harry E., Yarnall, D. Robert, Wood, Henry A. Wise, Coes, Harold V., Gantt, H. L., Jackson, Wm. B., Rogers, Fred E., Juthe, K. A., Barbour, Percy E., Alford, L. P., Hamilton, Chester B., Emerson, Harrington, Flanders, Ralph E., Williamson, C. S., De Leeuw, Adolph L., Caples, W. Goff, Miller, Fred J., Neff, Elmer H., Brophy, J. H., Wright, H. T., Riley, Lewis A., Kent, William, Henderson, Geo. R., and Miller, Spencer

Published
1916
Full Text
View/download PDF

47. (89)ZED88082A PET imaging to visualize CD8(+) T cells in patients with cancer treated with immune checkpoint inhibitor

Author

Ruijter, Laura Kist, Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Ungewickell, Alexander, Fine, Bernard M., Williams, Simon P., Bohorquez, Sandra M. Sanabria, Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey, Kimes, Patrick K., Glaudemans, Andor W., Brouwers, Adrienne H., Lub-De Hooge, Marjolijn N., Gietema, Jourik A., Schroder, Carolina P., Wim Timens, Jalving, Mathilde, Elias, Sjoerd, Oosting, Sjoukje F., Groot, Derk J., Vries, Elisabeth G., Translational Immunology Groningen (TRIGR), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Groningen Research Institute for Asthma and COPD (GRIAC), and Targeted Gynaecologic Oncology (TARGON)

48. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89 Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Author

Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G, Lyashchenko SK, Humm JL, Scher HI, Gönen M, Williams SP, Danila DC, and Morris MJ

Subjects
Aged, Aged, 80 and over, Humans, Immunoconjugates pharmacokinetics, Male, Middle Aged, Neoplasm Metastasis, Radiometry, Tissue Distribution, Antigens, Neoplasm immunology, Immunoconjugates immunology, Oxidoreductases immunology, Positron Emission Tomography Computed Tomography methods, Prostatic Neoplasms, Castration-Resistant diagnostic imaging, Prostatic Neoplasms, Castration-Resistant pathology, Radioisotopes, Zirconium
Abstract

Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified target in prostate cancer. We evaluated the ability of PET/CT with 89 Zr-DFO-MSTP2109A, an antibody that recognizes STEAP1, to detect lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: Nineteen mCRPC patients were prospectively imaged using approximately 185 MBq/10 mg of 89 Zr-DFO-MSTP2109A. 89 Zr-DFO-MSTP2109A PET/CT images obtained 4-7 d after injection were compared with bone and CT scans. Uptake in lesions was measured. Fifteen patients were treated with an antibody-drug conjugate (ADC) based on MSTP2109A; ADC treatment-related data were correlated with tumor uptake by PET imaging. Bone or soft-tissue biopsy samples were evaluated. Results: No significant toxicity occurred. Excellent uptake was observed in bone and soft-tissue disease. Median SUV max was 20.6 in bone and 16.8 in soft tissue. Sixteen of 17 lesions biopsied were positive on 89 Zr-DFO-MSTP2109A, and all sites were histologically positive (1 on repeat biopsy). Bayesian analysis resulted in a best estimate of 86% of histologically positive lesions being true-positive on imaging (95% confidence interval, 75%-100%). There was no correlation between SUV max tumor uptake and STEAP1 immunohistochemistry, survival after ADC treatment, number of ADC treatment cycles, or change in prostate-specific antigen level. Conclusion: 89 Zr-DFO-MSTP2109A is well tolerated and shows localization in mCRPC sites in bone and soft tissue. Given the high SUV in tumor and localization of a large number of lesions, this reagent warrants further exploration as a companion diagnostic in patients undergoing STEAP1-directed therapy., (© 2019 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2019
Full Text
View/download PDF

49. Pharmacokinetics and Biodistribution of a [ 89 Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

Author

O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G, Lyashchenko SK, Williams SP, Scher HI, Fine BM, Humm JL, Larson SM, Morris MJ, and Carrasquillo JA

Subjects
Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Cross Reactions immunology, Humans, Immunoglobulin G administration & dosage, Immunoglobulin G metabolism, Immunoglobulin G therapeutic use, Inhibitory Concentration 50, Injections, Intravenous, Male, Positron Emission Tomography Computed Tomography methods, Prospective Studies, Prostatic Neoplasms, Castration-Resistant blood, Prostatic Neoplasms, Castration-Resistant drug therapy, Radioisotopes administration & dosage, Radiopharmaceuticals administration & dosage, Tissue Distribution, Zirconium administration & dosage, Antibodies, Monoclonal, Humanized pharmacokinetics, Antigens, Neoplasm immunology, Bone Neoplasms diagnostic imaging, Bone Neoplasms secondary, Oxidoreductases immunology, Prostatic Neoplasms, Castration-Resistant diagnostic imaging, Radioisotopes pharmacokinetics, Radiopharmaceuticals pharmacokinetics, Soft Tissue Neoplasms diagnostic imaging, Soft Tissue Neoplasms secondary, Zirconium pharmacokinetics
Abstract

A six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a newly identified target in prostate cancer. The use of radio-labeled STEAP1-targeting antibodies with positron emission tomography (PET) may allow for detection of sites of metastatic prostate cancer and may refine patient selection for antigen-directed therapies. This was a prospective study in seven patients with metastatic castration-resistant prostate cancer who had at least one archival biopsy that was STEAP1-positive by immunohistochemistry. Patients received intravenous injections of ∼185 MBq and 10 mg of [ 89 Zr]Zr-DFO-MSTP2109A, a humanized IgG1 monoclonal antibody directed against STEAP1. PET/CT images, blood samples, and whole-body counts were monitored longitudinally in six patients. Here, we report on safety, biodistribution, pharmacokinetics, dose estimates to normal tissues, and initial tumor targeting for this group of patients. There was no significant acute or subacute toxicity. Favorable biodistribution and enhanced lesion uptake (in both bone and soft tissue) were observed on imaging using a mass of 10 mg of DFO-MSTP2109A. The best lesion discrimination was seen at the latest imaging time, a median of 6 days postadministration. Pharmacokinetics showed a median serum T 1/2 β of 198 h, volume of central compartment of 3.54 L (similar to plasma volume), and clearance of 19.7 mL/h. The median biologic T 1/2 for whole-body retention was 469 h. The highest mean absorbed doses to normal organs (mGy/MBq) were 1.18, 1.11, 0.78, 0.73, and 0.71 for liver, heart wall, lung, kidney, and spleen, respectively. Excellent targeting of metastatic prostate sites in both bone and soft tissue was observed, with an optimal imaging time of 6 days postadministration. The liver and heart were the normal organs that experienced the highest absorbed doses. The pharmacokinetics were similar to other antibodies without major cross-reactivity with normal tissues. A more detailed analysis of lesion targeting in a larger patient population with correlation to immunohistology and standard imaging modalities has been reported.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results